Deutsche Bank Ag\ Spruce Biosciences, Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.28 - $2.23 $15,740 - $27,422	-12,297 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.85 - $4.59 $12,985 - $32,217	7,019 Added 132.99%	12,297 $24,000
Q4 2021 Feb 11, 2022	BUY	$2.33 - $5.74 $652 - $1,607	280 Added 5.6%	5,278 $24,000
Q3 2021 Nov 04, 2021	SELL	$6.01 - $11.26 $1,123 - $2,105	-187 Reduced 3.61%	4,998 $30,000
Q2 2021 Aug 11, 2021	BUY	$10.12 - $17.46 $7,347 - $12,675	726 Added 16.28%	5,185 $58,000
Q1 2021 May 13, 2021	SELL	$14.8 - $25.79 $6,349 - $11,063	-429 Reduced 8.78%	4,459 $74,000
Q4 2020 Feb 16, 2021	BUY	$15.38 - $32.42 $75,177 - $158,468	4,888 New	4,888 $119,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.19M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.